https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49795 Wed 31 May 2023 15:25:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46788 Wed 30 Nov 2022 13:21:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50028 Wed 28 Jun 2023 09:49:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54134 Wed 28 Feb 2024 15:07:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50837 Wed 28 Aug 2024 08:42:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51394 Wed 28 Aug 2024 08:25:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39521 Wed 27 Jul 2022 14:01:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45277 0.14). Conclusion: In this secondary analysis of a primary efficacy study, PD was a common comorbidity among those with MDD, but was not a significant predictor of functional outcomes. This study adds to the limited literature on PD in randomized controlled trials for MDD.]]> Wed 26 Oct 2022 17:13:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45043 n = 717) were administered the Structured Clinical Interview for DSM-IV (SCID-I/NP and SCID-II) and the World Health Organisation Quality of Life scale (WHOQOL-BREF). Weight and height were measured and lifestyle and demographic factors were self-reported. Logistic regression models (odds ratios with 95% confidence intervals) were undertaken to investigate associations among groups (mental state disorders, co-occurring mental state disorders with PD, and controls) and the WHOQOL-BREF domains (physical, psychological, social, and environmental health) while testing for potential confounding. Results: Results indicated that mental state disorders were associated with increased risk of low quality of life in physical, psychological, social, but not environmental domains, compared to controls. This risk was increased among women with co-occurring PD across all domains compared to both controls and those with mental state disorders. Conclusion: These findings add evidence suggesting poor quality of life is experienced by those with mental state disorders, and that this is worsened by the experience of co-occurring PD.]]> Wed 26 Oct 2022 12:00:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50458 Wed 26 Jul 2023 13:35:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36899 Wed 24 Nov 2021 15:53:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50683 Wed 24 Apr 2024 11:33:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44465 Wed 22 Feb 2023 13:51:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13795 13 on the Beck Depression Inventory-II (BDI-II) received a single-session brief intervention. They were then block randomised to either six sessions of group CBT (n = 25) or no further intervention (BI; n = 32). All were re-assessed at 2, 6 and 12 months. Differences between treatment groups in the primary (BDI-II) and secondary [rates of depression; anxiety symptoms, as measured by the Hospital Anxiety and Depression Scale-Anxiety (HADS-A)] outcomes were examined using generalised linear mixed models with a random intercept term for the individual. Results: Significant improvements were seen for the total group from baseline to 12 months on BDI-II and HADS-A scores. However, no differences were found between the CBT and BI conditions on change in BDI-II score, rates of major depressive episode or HADS-A score. Post hoc analysis on the total group found 12-month symptom non-remission was associated with higher baseline BDI-II score (p = 0.03), more visits to health professionals 12 months prior to baseline (p = 0.05) and a greater likelihood of either drinking alcohol over recommended levels or smoking at baseline (p = 0.01). Conclusions: Group CBT of up to six sessions did not result in greater reductions in depression or anxiety symptoms compared with a single-session brief intervention. Further work should focus on the efficacy and role of brief interventions, and addressing smoking and alcohol misuse in cardiac patients with depression.]]> Wed 18 Sep 2024 14:11:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38957 Wed 16 Mar 2022 14:12:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51028 Wed 16 Aug 2023 10:09:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36511 Wed 15 Jul 2020 18:30:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49889 Wed 14 Jun 2023 17:31:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51397 Wed 13 Mar 2024 08:05:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:33194 Wed 12 Sep 2018 09:36:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22895 Wed 11 Apr 2018 09:57:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:32229 Wed 10 Nov 2021 15:13:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36597 Wed 10 Jun 2020 15:12:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53737 Wed 10 Jan 2024 11:31:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39815 I² statistic. This systematic review was registered with PROSPERO (CRD42018089279) and the protocol is published. Results: The search yielded 11,640 studies. Subsequent to removing duplicates, 9657 studies were screened at title and abstract stage and 1456 were assessed at full-text stage. Eighteen studies met criteria for inclusion in this review. Meta-analysis did not reveal a significant difference between groups for treatment outcome (standardised mean difference 0.22 [-0.09, 0.54]; I²: 69%, p=0.17) and remission (risk ratio 0.84 [0.64, 1.11]; I²: 51%, p=0.22). Limitations: This review was limited by lack of studies on bipolar disorder. Conclusion: PD comorbidity does not appear to affect treatment efficacy of pharmacological interventions for adults with mood disorders.]]> Wed 10 Aug 2022 13:16:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53619 Wed 07 Feb 2024 14:40:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50157 Wed 05 Jul 2023 15:21:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50150 50% at baseline). Untargeted gas chromatography–mass spectrometry analysis was performed to analyse baseline levels of 68 serum metabolites. Of the nine metabolites that differentiated placebo and NAC groups, five were amino acids with lower levels in the NAC responder group compared with the NAC non-responders. Further analysis generated a predictive model of MADRS improvement including glycine, norleucine, threonine, proline, phenylalanine, tyrosine, glutamic acid, lysine and leucine (R2 = 0.853; adjusted R2 = 0.733). This prediction model predicted 85% of the variance in MADRS outcome after adjunctive treatment with NAC. BD participants with lower serum levels of free amino acids at baseline may be more likely to respond to adjunctive treatment with NAC.]]> Wed 05 Jul 2023 14:11:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48692 Tue 28 Mar 2023 20:45:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42444 Tue 23 Aug 2022 11:15:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51126 Tue 22 Aug 2023 15:51:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51127 Tue 22 Aug 2023 15:51:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15660 Tue 16 Oct 2018 13:11:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51427 Tue 05 Sep 2023 17:47:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38082 2^{[22, n = 312]} = 76.43, P ' 0.02). Internal consistency analyses indicated acceptable internal reliability (Self-Reflection a = 0.73, Self-Certainty a = 0.72, composite a = 0.75). Self-Certainty scores were significantly higher for participants with a self-reported psychotic disorder (M = 14.95 vs. M = 13.04, P = 0.007). Self-Reflection scores were higher for people experiencing psychological distress (M = 17.57 vs. M = 15.95, P = 0.001). Discussion and Conclusions: We found that a 12-item version of the BCIS had good psychometric properties in this substance-using population. Further research is needed to explore whether insight can predict treatment outcomes for substance use.]]> Tue 03 Aug 2021 18:14:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54905 Thu 21 Mar 2024 11:56:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:35335 Thu 17 Mar 2022 14:34:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54278 Thu 15 Feb 2024 14:38:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:30146 Thu 13 Jan 2022 10:31:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50913 Thu 10 Aug 2023 15:24:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:31135 Thu 09 Dec 2021 11:01:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38922 Thu 05 Sep 2024 09:44:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38559 Thu 04 Nov 2021 11:03:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41579 Thu 04 Apr 2024 11:48:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41248 Sat 30 Jul 2022 12:40:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8111 Sat 24 Mar 2018 08:40:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7240 Sat 24 Mar 2018 08:33:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1340 Sat 24 Mar 2018 08:32:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:2966 Sat 24 Mar 2018 08:30:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:11095 Sat 24 Mar 2018 08:13:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18235 Sat 24 Mar 2018 08:04:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:19580 Sat 24 Mar 2018 07:58:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:28072 Sat 24 Mar 2018 07:39:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27367 Sat 24 Mar 2018 07:36:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:26171 Sat 24 Mar 2018 07:30:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49523 Sat 20 May 2023 12:39:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38937 SD = 2.6; out of 8-sessions). Seventeen participants (77%) completed at least half of the sessions, and nine participants (40%) completed all eight sessions. Participant satisfaction was high, with all participants followed up rating the quality of the service they received as 'good' or 'excellent'. When compared to the Control Condition, people in the Treatment Condition demonstrated greater treatment effects on smoking and leisure screen time. There was only a negligible effect on servings of fruit and vegetable. Conclusions: Results were promising regarding the feasibility of peer-workers delivering BHC. Good retention rates and high consumer satisfaction ratings in the Treatment Condition demonstrated that peer-workers were capable of delivering the intervention to the extent that consumers found it beneficial. The current results suggest that a sufficiently powered, peer delivered randomised controlled trial of BHC is warranted.]]> Mon 29 Jan 2024 18:03:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38574 Mon 29 Jan 2024 17:57:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38081 Mon 29 Apr 2024 13:46:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27031 Mon 23 Sep 2019 12:39:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39177 n = 133). Participants received 16 weeks adjunctive treatment of either placebo or N-acetylcysteine-alone or a combination of mitochondrial-enhancing nutraceuticals including N-acetylcysteine (combination treatment). Participants were followed up 4 weeks post-treatment discontinuation (Week 20). Diet was assessed by the Cancer Council Victoria Dietary Questionnaire for Epidemiological Studies, Version 2, converted into an Australian Recommended Food Score to measure diet quality, and energy-adjusted dietary inflammatory index score to measure inflammatory potential of diet. Body mass index was also measured. Generalised estimating equation models were used to assess whether diet quality, energy-adjusted dietary inflammatory index score and/or body mass index were predictors of response to significant outcomes of the primary trial: depression symptoms, clinician-rated improvement and functioning measures. Results: In participants taking combination treatment compared to placebo, change in depression scores was not predicted by Australian Recommended Food Score, dietary inflammatory index or body mass index scores. However, participants with better diet quality (Australian Recommended Food Score) reported reduced general depression and bipolar depression symptoms (p = 0.01 and p = 0.03, respectively) and greater clinician-rated improvement (p = 0.02) irrespective of treatment and time. Participants who had a more anti-inflammatory dietary inflammatory index had less impairment in functioning (p = 0.01). Combination treatment may attenuate the adverse effects of pro-inflammatory diet (p = 0.03) on functioning. Participants with lower body mass index who received combination treatment (p = 0.02) or N-acetylcysteine (p = 0.02) showed greater clinician-rated improvement. Conclusion: These data support a possible association between diet (quality and inflammatory potential), body mass index and response to treatment for bipolar depression in the context of a nutraceutical trial. The results should be interpreted cautiously because of limitations, including numerous null findings, modest sample size and being secondary analyses.]]> Mon 23 May 2022 14:53:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49563 0.05). After adjustment for demographic differences, participants who smoked had lower craving [b (SE) = −1.1 (0.5), P = 0.021] and were less likely to report psychotic symptoms [b (SE) = −1.8 (0.7), P = 0.013] or antidepressant use [b (SE) = −1.1 (0.5), P = 0.022]. Discussion and Conclusions: Smoking crystalline methamphetamine is associated with a younger less marginalised demographic profile than injecting methamphetamine, but a similarly severe clinical profile.]]> Mon 22 May 2023 09:20:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52335 Mon 09 Oct 2023 14:50:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48223 75 years were significantly less likely to use social media compared with those aged <55 years (adjusted odds ratio 0.17, 95% CI 0.07-0.44). Health risk factors were not found to be associated with searching for health- or medical-related information. Conclusions: The internet appears to be a viable platform to engage with stroke survivors who may not be high-morbidity to conduct research and provide information and health interventions. This is important given that they are at high risk of recurrent stroke regardless of their level of disability. Exploring the technology use behaviors and the possibility of eHealth among survivors who experience higher levels of morbidity or disability because of their stroke is an area of research that warrants further study.]]> Mon 08 May 2023 10:35:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51396 Mon 04 Sep 2023 14:43:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51391 Mon 04 Sep 2023 13:47:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45466 n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes. Results: There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change. Conclusions: Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted.]]> Fri 28 Oct 2022 14:45:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48649 Fri 24 Mar 2023 15:57:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38673 N = 27). At cutoff 10, the PHQ-8 was less sensitive by 0.02 (−0.06 to 0.00) and more specific by 0.01 (0.00 to 0.01) among those studies (N = 27), with similar results for studies that used other types of interviews (N = 27). For all 54 primary studies combined, across all cutoffs, the PHQ-8 was less sensitive than the PHQ-9 by 0.00 to 0.05 (0.03 at cutoff 10), and specificity was within 0.01 for all cutoffs (0.00 to 0.01). Conclusions: PHQ-8 and PHQ-9 total scores were similar. Sensitivity may be minimally reduced with the PHQ-8, but specificity is similar.]]> Fri 22 Apr 2022 15:27:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51700 Fri 15 Sep 2023 10:39:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:24438 Fri 03 Dec 2021 10:35:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51362 Fri 01 Sep 2023 13:44:30 AEST ]]>